{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-015159","form_type":"8-K","ticker":"SSKN","cik":"0001051514","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.676584+00:00","generated_at":"2026-06-17T07:33:12.657006+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"STRATA Skin Sciences reports record Q4 revenue of $10.6M; FY 2023 guidance $38M-$40M","bullets":["Q4 2022 revenue $10.6M (+17% YoY); full-year revenue $36.2M (+21% YoY).","Net loss narrowed to $0.2M in Q4 ($0.005/share) vs $0.8M loss in Q4 2021; full-year net loss $5.5M vs $2.7M.","Domestic installed base of 909 XTRAC devices; acquired TheraClearX acne device in Jan 2022.","FY 2023 revenue guidance of $38M-$40M; entered Mexican market with distribution agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-015159","json":"https://secwatch.observer/filing/0001140361-23-015159.json","markdown":"https://secwatch.observer/filing/0001140361-23-015159.md","text":"https://secwatch.observer/filing/0001140361-23-015159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123015159/0001140361-23-015159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123015159/brhc10050694_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:33:12.657006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05341512b2330072aebd08988da0e6814dc82ad0","claim":"STRATA Skin Sciences, Inc. reported the fourth fiscal quarter and full year ended December 31, 2022 results: revenue $10.6 million, net income Net loss for the fourth quarter of 2022 was $0.2 million, or a loss of $0.005 per basic and diluted common share, EPS loss of $0.005 per basic and diluted common share. Guidance raised.","evidence_excerpt":"results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Highlights: ● Revenue in the fourth quarter of 2022 was a record $10.6 million, an increase of 17% over the fourth quarter of 2021 ○ Global recurring revenue was $6.5 million ○ Gross domestic recurring billings were $5.8 million ● Revenue for the full year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123015159/0001140361-23-015159-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth fiscal quarter and full year ended December 31, 2022"},{"label":"Revenue","value":"$10.6 million"},{"label":"Net income","value":"Net loss for the fourth quarter of 2022 was $0.2 million, or a loss of $0.005 per basic and diluted common share"},{"label":"EPS","value":"loss of $0.005 per basic and diluted common share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c8feea47fda821ea0e177f396e4ffbb7a1b345ee","claim":"STRATA Skin Sciences, Inc. reported the fiscal year ended December 31, 2022 results: revenue $36.2 million, net income Net loss for the full year 2022 was $5.5 million, or a loss of $0.16 per basic and diluted common share, EPS loss of $0.16 per basic and diluted common share. Guidance raised.","evidence_excerpt":"Revenues for the full year 2022 were $36.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036123015159/0001140361-23-015159-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$36.2 million"},{"label":"Net income","value":"Net loss for the full year 2022 was $5.5 million, or a loss of $0.16 per basic and diluted common share"},{"label":"EPS","value":"loss of $0.16 per basic and diluted common share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}